Chengdu Huasun Group Inc Ltd Market Cap ($322.18 Million)
Market Cap & Net Worth: Chengdu Huasun Group Inc Ltd (000790)
Chengdu Huasun Group Inc Ltd market cap. Chengdu Huasun Group Inc Ltd (SHE:000790) has a market capitalization of $322.18 Million (CN¥2.20 Billion) as of November 1, 2026. Listed on the SHE stock exchange, this China-based company holds position #14167 globally and #4166 in its home market, demonstrating a -4.59% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Chengdu Huasun Group Inc Ltd's stock price CN¥3.53 by its total outstanding shares 623719364 (623.72 Million). Also see 000790 cash flow conversion for how efficiently the company converts equity into cash flow.
Chengdu Huasun Group Inc Ltd Market Cap History (2015–2026)
Chengdu Huasun Group Inc Ltd market cap history from 2015 to 2026. Data shows change from $1.02 Billion to $322.18 Million (-6.07% CAGR). Check Chengdu Huasun Group Inc Ltd share price for real-time trading data and today's change.
Chengdu Huasun Group Inc Ltd Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Chengdu Huasun Group Inc Ltd's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Explore net asset growth rate of Chengdu Huasun Group Inc Ltd to track how rapidly the company is growing its equity base year over year.
Latest Price to Sales (P/S) Ratio
0.41x
Chengdu Huasun Group Inc Ltd's market cap is 0.41 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2015 | $1.02 Billion | $463.31 Million | -$37.41 Million | 2.21x | N/A |
| 2016 | $817.96 Million | $575.19 Million | $82.50 Million | 1.42x | 9.91x |
| 2017 | $457.12 Million | $590.95 Million | $171.67 Million | 0.77x | 2.66x |
| 2018 | $331.25 Million | $633.42 Million | $31.17 Million | 0.52x | 10.63x |
| 2019 | $408.91 Million | $745.34 Million | $61.63 Million | 0.55x | 6.63x |
| 2020 | $398.00 Million | $759.31 Million | $37.50 Million | 0.52x | 10.61x |
| 2021 | $576.38 Million | $954.94 Million | $55.63 Million | 0.60x | 10.36x |
| 2022 | $413.21 Million | $873.10 Million | $41.22 Million | 0.47x | 10.03x |
| 2023 | $460.44 Million | $1.00 Billion | $27.66 Million | 0.46x | 16.65x |
| 2024 | $355.95 Million | $863.98 Million | -$6.69 Million | 0.41x | N/A |
Competitor Companies of 000790 by Market Capitalization
Companies near Chengdu Huasun Group Inc Ltd in the global market cap rankings as of November 1, 2026. Also see 000790 total assets for a full breakdown of the balance sheet.
Key companies related to Chengdu Huasun Group Inc Ltd by market ranking:
- Takeda Pharmaceutical Co Ltd ADR (NYSE:TAK): Ranked #511 globally with a market cap of $52.60 Billion USD.
- GALDERMA GROUP AG (NYSE:GALDY): Ranked #535 globally with a market cap of $50.42 Billion USD.
- Jiangsu Hengrui Medicine Co Ltd (SHG:600276): Ranked #593 globally with a market cap of $45.23 Billion USD ( CN¥309.13 Billion CNY).
- Takeda Pharmaceutical Company Limited (F:TKDA): Ranked #619 globally with a market cap of $43.60 Billion USD ( €37.29 Billion EUR).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #511 | Takeda Pharmaceutical Co Ltd ADR | NYSE:TAK | $52.60 Billion | $16.65 |
| #535 | GALDERMA GROUP AG | NYSE:GALDY | $50.42 Billion | $46.62 |
| #593 | Jiangsu Hengrui Medicine Co Ltd | SHG:600276 | $45.23 Billion | CN¥48.46 |
| #619 | Takeda Pharmaceutical Company Limited | F:TKDA | $43.60 Billion | €18.30 |
Market Capitalization of Chengdu Huasun Group Inc Ltd (2015–2026)
Market capitalization of Chengdu Huasun Group Inc Ltd from 2015 to today. Between 2015 and today, Chengdu Huasun Group Inc Ltd's market cap moved from $1.02 Billion to $ 322.18 Million, with a yearly change of -6.07%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | CN¥322.18 Million | -8.79% |
| 2025 | CN¥353.21 Million | -0.77% |
| 2024 | CN¥355.95 Million | -22.69% |
| 2023 | CN¥460.44 Million | +11.43% |
| 2022 | CN¥413.21 Million | -28.31% |
| 2021 | CN¥576.38 Million | +44.82% |
| 2020 | CN¥398.00 Million | -2.67% |
| 2019 | CN¥408.91 Million | +23.45% |
| 2018 | CN¥331.25 Million | -27.54% |
| 2017 | CN¥457.12 Million | -44.12% |
| 2016 | CN¥817.96 Million | -20.18% |
| 2015 | CN¥1.02 Billion | -- |
End of Day Market Cap According to Different Sources
On Oct 31st, 2026 the market cap of Chengdu Huasun Group Inc Ltd was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $322.18 Million USD |
| MoneyControl | $322.18 Million USD |
| MarketWatch | $322.18 Million USD |
| marketcap.company | $322.18 Million USD |
| Reuters | $322.18 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Chengdu Huasun Group Inc Ltd
Chengdu huasun technology group Inc. , LTD. manufactures and sells medicines, bio-pharmaceutical products, and building steel structures. The company manufactures modern Chinese medicines, Chinese patent medicines, chemical medicines, and drugs. It also engages in the research and development, production, and sale of biological products and biotechnology drugs; and medicines for the treatment of … Read more